Partners and Collaborations
In parallel to running our in-house programs, Anima has strategically structured itself to collaborate with Pharma partners on their existing or new programs. Our technology platform provides our partners with a new strategy to approach hard and "undruggable" targets in a wide range of indications. In this collaboration model, we combine the power of our technology platform with the pre-clinical, clinical and financial capabilities of a pharma partner to build a long-term partnership around one or more drug discovery programs in their area of interest.
For partnering inquiries, please contact [email protected].
Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform. The multi-year agreement is structured as a strategic collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.
Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
Anima Biotech announces strategic collaboration with Takeda to discover and develop mRNA translation modulators for Neurological diseases
Anima Biotech announced an agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop mRNA translation modulators for Neurological diseases. Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize. The preclinical research collaboration will initially include Anima’s early Huntington’s Disease program against the HTT target, selectively inhibiting the mutated protein with small molecules and two additional targets named by Takeda, related to neurological diseases. Takeda will pay Anima up to approximately $120 million in upfront and preclinical research milestone payments and up to $1.1 billion in clinical and commercial milestones, assuming success of the three programs. Anima is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Takeda has a time limited option to expand the collaboration with up to three additional targets subject to additional payments to Anima of up to $1.2 billion and tiered royalties, assuming success of these programs.
Scientific collaboration network
Through our collaboration programs we continuously expand the scope of our technology and validate it in new therapeutic areas. 17 partners are collaborating with us on Translationlight related research that has so far resulted in 15 publications in leading journals with additional publications in the pipeline.
- Duke University
- Oxford University
- The Scripps Research Institute
- Alma Mater Studiorum Università di Bologna
- Consiglio Nazionale delle Ricerche
- Gutenberg University
- Haifa University
- Hamburg University
- Jefferson University
- Massachusetts General Hospital
- Penn University
- Tel-Aviv University
- Texas University
- Torino University
- Western University